Overview

* Inogen Q3 revenue grows 4% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q3 beats analyst estimates, reflecting improved operational performance

* Company reiterates full-year revenue guidance, raises adjusted EBITDA outlook

Outlook

* Inogen reiterates full-year revenue guidance of $354 mln to $357 mln

* Company raises full-year adjusted EBITDA guidance to approximately $2 mln

* Inogen expects Q4 revenue between $87 mln and $90 mln

Result Drivers

* BUSINESS-TO-BUSINESS SALES - Increased demand from international and domestic B2B customers drove revenue growth

* COST MANAGEMENT - Decrease in operating expenses due to ongoing cost management efforts

* NEW PRODUCT RELEASE - Initiated limited market release of Simeox airway clearance device in the U.S.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $92.40 $92.20

Revenue mln mln (2

Analysts

)

Q3 Beat -$500,00 -$5.90

Adjusted 0 mln (2

Net Analysts

Income )

Q3 Net -$5.30

Income mln

Q3 Beat $2.30 $750,000

Adjusted mln (2

EBITDA Analysts

)

Q3 Gross 44.70%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Inogen Inc ( INGN ) is $13.00, about 38% above its November 4 closing price of $8.06

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)